Canadian Fertility Oversight Litigation: Regulatory Vacuum Spurs Legal Challenges

• Canada's fertility sector is rapidly growing but remains one of the country's least supervised healthcare areas.
• The 2004 Assisted Human Reproduction Act's national oversight vision was narrowed by a 2010 Supreme Court ruling, shifting clinical practice oversight to provinces, which have not adequately filled the gap.
• Litigation, including class actions and wrongful pregnancy claims, is increasingly being used to address regulatory deficiencies and provide accountability in the fertility sector.
• Experts highlight a lack of scrutiny over commercial claims and products marketed to patients, contrasting with the regulation of physician clinical decisions.
• Inconsistent provincial oversight, such as in Ontario where embryologists lack mandatory licensing and public reporting is absent, contributes to patient challenges and legal disputes.

This reliance on legal action highlights a critical gap, as courts are increasingly tasked with resolving issues that regulatory frameworks have left unaddressed.

Canada's fertility care landscape has experienced rapid expansion, yet the regulatory structures intended to govern it have not kept pace. This disparity has led to courts increasingly grappling with complex issues that extend beyond mere individual negligence claims. As more Canadians postpone parenthood, face infertility, or seek broader reproductive choices, the demand for assisted reproductive technology continues to climb, offering significant hope and options that were previously unavailable.

Despite its vital role, the Canadian fertility sector stands out as one of the nation's fastest-growing healthcare segments, simultaneously being among the least supervised. Patients navigating this system are frequently confronted with intricate medical and financial decisions. This environment is characterized by a convergence of clinical evidence, commercial incentives, and deeply personal aspirations, often resulting in inconsistent information, difficulty comparing treatment options, and the promotion of expensive tests or add-on procedures with claims that frequently exceed scientific backing. Concerns are also mounting regarding persistent inequities in access and adherence to evidence-based medical practices.

The current regulatory challenges stem partly from historical legislative efforts. When the Assisted Human Reproduction Act was enacted by Parliament in 2004, it aimed to establish a comprehensive national oversight regime. However, a pivotal 2010 ruling by the Supreme Court of Canada, in Reference re Assisted Human Reproduction Act, significantly curtailed federal authority. The Court determined that many of the Act's regulatory provisions intruded upon provincial jurisdiction over healthcare, thereby narrowing the federal government's scope.

This judicial decision created a substantial regulatory vacuum, which provinces have largely failed to address. The resulting fragmented approach has had considerable consequences. While the federal framework continues to prohibit practices such as human cloning and the commercial sale of reproductive material, the responsibility for overseeing clinical practice predominantly shifted to provincial authorities. Unfortunately, provincial oversight remains inconsistent and often inadequate across the country.

In the absence of robust regulatory frameworks, litigation is increasingly being leveraged to provide accountability when issues arise. Jan Marin, a senior associate at Gluckstein Lawyers, observes that while fertility medicine has made remarkable advancements, the commercial industry surrounding it has outpaced the existing oversight mechanisms. She notes that while physicians and their clinical decisions are regulated, there is considerably less scrutiny applied to the products, technologies, and commercial claims directed at patients. The concern is not with innovation itself, but with the growing reliance on legal action to ensure accountability after harm has already occurred.

This reliance on legal action highlights a critical gap, as courts are increasingly tasked with resolving issues that regulatory frameworks have left unaddressed. For instance, class actions concerning preimplantation genetic testing are currently progressing through courts in both the United States and Canada. Canadian judges are being called upon to make determinations in this evolving area of law, effectively testing whether consumer protection and tort law can compensate for the deficiencies in health oversight.

The distinction between a physician's clinical judgment and a company's marketing of a product is crucial. While a doctor may reasonably recommend varying treatments, commercial claims for tests purporting to improve a patient's chance of conception should be substantiated by reliable scientific evidence. The mere fact that a product is sold within a medical setting should not exempt it from rigorous examination.

Specific examples underscore these regulatory shortcomings. In Ontario, fertility clinics are predominantly privately operated, embryologists are not subject to mandatory professional licensing, and there is no standardized public reporting system to enable patients to compare clinic performance or treatment outcomes. Furthermore, wrongful pregnancy claims across Canada continue to yield inconsistent judicial decisions, with judges differing on whether damages should be confined to pregnancy-related losses or extended to cover the costs associated with raising a child. These cases, while raising complex questions about reproductive autonomy and negligence, collectively illustrate the broader trend of litigation becoming the primary mechanism for resolving issues in this under-regulated sector.

Lawyers and compliance officers should note the increasing reliance on litigation (tort, consumer protection, class actions) to address regulatory gaps in the Canadian fertility sector. This necessitates close monitoring of evolving case law and potential for new claims, especially given the fragmented federal and provincial oversight and the lack of clear regulatory frameworks for commercial aspects of fertility treatment and clinic operations.

Source: Original reporting via The Globe and Mail